Company news

Equillium, Inc. news in 2025

Equillium, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Equillium to Participate in Upcoming Investor Conferences

November 20, 2025

Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

November 13, 2025

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

October 22, 2025

Equillium Announces Leadership and Corporate Updates

October 6, 2025

Equillium to Participate in the Cantor Global Healthcare Conference 2025

August 29, 2025

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

August 11, 2025

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

August 3, 2025

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

May 6, 2025

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

May 1, 2025

Equillium Announces Feedback from the U.S. Food and Drug Administration

April 24, 2025

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

March 27, 2025

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

March 27, 2025

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

February 5, 2025

Decks in 2025